142 related articles for article (PubMed ID: 37943630)
1. Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model.
Mohan AM; Prasad S; Schmitz-Peiffer F; Lange C; Lukas M; Koziolek EJ; Albrecht J; Messroghli D; Stein U; Ilmer M; Wang K; Schober L; Reul A; Maurer J; Friemel J; Weber A; Zuellig RA; Hantel C; Fritsch R; Reincke M; Pacak K; Grossman AB; Auernhammer CJ; Beuschlein F; Brenner W; Beindorff N; Nölting S
Endocr Relat Cancer; 2024 Jan; 31(1):. PubMed ID: 37943630
[TBL] [Abstract][Full Text] [Related]
2. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
4. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
5. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
[TBL] [Abstract][Full Text] [Related]
8. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
10. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
11. Target therapies plus somatostatin analogs in NETs: a network meta-analysis.
Pusceddu S; Facciorusso A; Giacomelli L; Prinzi N; Corti F; Niger M; Milione M; Coppa J; Cascella T; Pulice I; Biamonte L; Papa S; Di Bartolomeo M; Shah A; Sacco R; de Braud F
Endocr Relat Cancer; 2021 Jun; 28(7):467-479. PubMed ID: 33979777
[TBL] [Abstract][Full Text] [Related]
12. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
[TBL] [Abstract][Full Text] [Related]
13. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
[TBL] [Abstract][Full Text] [Related]
17. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
18. MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells.
Terracciano F; Capone A; Montori A; Rinzivillo M; Partelli S; Panzuto F; Pilozzi E; Arcidiacono PG; Sette C; Capurso G
Neuroendocrinology; 2021; 111(8):739-751. PubMed ID: 32615570
[TBL] [Abstract][Full Text] [Related]
19. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel ME; Singh S; Strosberg JR; Bubuteishvili-Pacaud L; Degtyarev E; Neary MP; Carnaghi C; Tomasek J; Wolin E; Raderer M; Lahner H; Valle JW; Pommier R; Van Cutsem E; Tesselaar MET; Fave GD; Buzzoni R; Hunger M; Eriksson J; Cella D; Ricci JF; Fazio N; Kulke MH; Yao JC
Lancet Oncol; 2017 Oct; 18(10):1411-1422. PubMed ID: 28838862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
